Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for active acromegaly
ACTRN12610000780055Phase 2Completed
- Sponsor
- Auckland District Health Board
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pioglitazone in acromegaly, sponsored by Auckland District Health Board. Primary endpoint: Change in insulin-like growth factor 1. Started Jun 2009; status: completed.
02
Drugs
pioglitazone
03
Conditions
acromegaly
Beyond the preview
Go deeper on ACTRN12610000780055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000780055.